Getein Biotech

Getein Biotech Liabilities

The The Liabilities of Getein Biotech (603387.SS) as of Oct 13, 2026 is 896.55 M CNY. In the previous year, The Liabilities was 986.42 M CNY — a change of -9.11% (lower).

Liabilities

896.55 MCNY

YoY

-9.11%

Last updated:

In 2025, Getein Biotech's total liabilities amounted to 896.55 M CNY, a -9.11% difference from the 986.42 M CNY total liabilities in the previous year.

The Getein Biotech Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
187.23 M CNY
Jan 1, 2019
325.98 M CNY
Jan 1, 2020
695.95 M CNY
Jan 1, 2021
863.90 M CNY
Jan 1, 2022
1.01 B CNY
Jan 1, 2023
1.03 B CNY
Jan 1, 2024
986.42 M CNY
Jan 1, 2025
896.55 M CNY
The Getein Biotech Liabilities history
YEARLiabilitiesYoY
896.55 MCNY-9.11%
986.42 MCNY-4.27%
1.03 BCNY+1.73%
1.01 BCNY+17.24%
863.90 MCNY+24.13%
695.95 MCNY+113.49%
325.98 MCNY+74.11%
187.23 MCNY+57.50%
118.87 MCNY+30.45%
91.13 MCNY+53.21%
59.48 MCNY+44.16%
41.26 MCNY—
Access this data via the Eulerpool API
Get Free API Key

Getein Biotech Stock analysis

What does Getein Biotech do? Getein Biotech is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Getein Biotech's Liabilities

Getein Biotech's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Getein Biotech's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Getein Biotech's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Getein Biotech's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Getein Biotech’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Getein Biotech stock

The Liabilities of Getein Biotech is 896.55 M CNY in 2025.

The Liabilities of Getein Biotech changed from 986.42 M CNY to 896.55 M CNY, representing a -9.11% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Getein Biotech since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Getein Biotech historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Getein Biotech

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Getein Biotech